



12-14-04

Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Friesen, et al.
Serial No: 10/774,781
Filed: February 9, 2004
For: Composition and Method for Use in Cartilage Affecting Conditions
Confirmation No: 8857
Art Unit: 1614
Examiner: TBA
HDP Ref: 2664H-000020/US
Hills Ref: IR 7457-00

December 13, 2004

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.5, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b), and, in the course of such search, will

EV 317349575 00

review for relevance every document listed on the attached form even if not initialed.

Some references cited in this information disclosure statement are U.S. Patents. Copies of those references are not being provided in accordance with MPEP §609 Part III(A)(2)(A). Applicants, however, will provide copies of such references upon request from the Examiner. The remaining reference articles are included for the Examiner. The references that are enclosed with this information disclosure statement are identified as being enclosed on the Form 1449.


Applicants request early and favorable consideration.

* * * * *

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



James E. Davis, PTO Reg. No. 47,516
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)



TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/774,781
	Filing Date	February 9, 2004
	First Named Inventor	Friesen, et al.
	Art Unit	1614
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	(7457) 2664H-20/US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449 5 References Return Postcard
Remarks: The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750. A duplicate copy of this sheet is enclosed.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name	Harness, Dickey & Pierce, P.L.C.	Attorney Name James E. Davis	Reg. No. 47,516
Signature			
Date	December 13, 2004		

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	James E. Davis	Express Mail Label No.	EV 317349575 US
Signature		Date	December 13, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 317349575 US

Appl. No. 10/774,781
Information Disclosure Statement
December 13, 2004



CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **December 13, 2004** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.

A handwritten signature, appearing to be "J. E. A.", is written over a horizontal line.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

Sheet 1 of 1

ATTORNEY DOCKET No.

(7457) 2664H-000020/US

SERIAL No.

10/774,781

APPLICANT

Friesen, et al.

FILING DATE

February 9, 2004

GROUP

1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		5,587,363	12/24/96	Henderson	514/54	
2.		6,255,295	7/03/01	Henderson, et al.	514/54	
3.		6,271,213	8/07/01	Henderson, et al.	514/53	

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
4.		Beren, et al.; Effect of Pre-Loading Oral Glucosamine HCL/Chondroitin Sulfate/Manganese Ascorbate Combination on Experimental Arthritis in Rats, <i>Experimental Biology and Medicine</i> , Vol. 226, pp.144-151, 2001
5.		Kroger, et al.; The Effect of Tryptophan Plus Methionine, 5-Azacytidine, and Methotrexate on Adjuvant Arthritis of Rat; <i>General Pharmacology</i> , Vol. 33, No. 2, pp. 195-201, August 1999
6.		Soeken, et al.; Safety and Efficacy of S-Adenosylmethionine (SAME) for Osteoarthritis: a Meta-Analysis; <i>Journal of Family Practice</i> , Vol. 51, No. 5, May 2002
7.		Takizawa, et al.; Production of Tissue Inhibitor of Metalloproteinases 3 Is Selectively Enhanced by Calcium Pentosan Polysulfate in Human Rheumatoid Synovial Fibroblasts; <i>Arthritis Rheum.</i> , Vol. 43, No. 4, pp. 812-820, April 2000
8.		Yen, et al.; Manganese Superoxide Dismutase and Cytochrome P450 1A1 Genes Polymorphisms in Rheumatoid Arthritis in Taiwan; <i>Human Immunology</i> , Vol. 64, No. 3, pp.366-373, March 2003

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 317349575 US